Alnylam's sales momentum is being watched to see if it can be sustained, potentially with the help of its drug Amvuttra. The company has announced FDA approval of Amvuttra, an RNAi therapeutic for adults with a specific type of amyloidosis. It is unclear how Alnylam's earnings and sales will be affected, as the company has reported a mix of beating earnings and missing sales despite year-over-year growth.